Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06818812 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
A Phase 1 study of Solid Tumors, sponsored by Incyte Corporation.
- Active
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 9
- Study locations
NCT06818812: Active Phase 1 study of Solid Tumors, sponsored by Incyte Corporation.
NCT06818812 is a Phase 1 study of Solid Tumors that is active but no longer recruiting, run by Incyte Corporation. The registered enrollment target is 30 participants, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (89% lower). The trial reports 9 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06818812, a Phase 1 study of Solid Tumors, is active but no longer recruiting, sponsored by Incyte Corporation.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 9
- Study locations
Study Summary
The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation.
Primary Outcome
Dose-limiting toxicity will be defined as the occurrence of any of the toxicities as per protocol.
Conditions Studied
Interventions
- DRUG Cetuximab
- DRUG mFOLFIRINOX
- DRUG GEMNabP
- DRUG INCB186748
Study Locations (9)
California
- UCLA Healthcare Hematology-Oncology - Santa Monica
Colorado
- Sarah Cannon Research Institue At Healthone - Denver
District of Columbia
- Georgetown University Hospital - Washington D.C.
Florida
- Florida Cancer Specialists - Sarasota
Maryland
- Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins - Baltimore
New Jersey
- Hackensack University Medical Center - Hackensack
Pennsylvania
- Jefferson University Hospitals - Philadelphia
Tennessee
- Scri Oncology Partners - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-03-27 |
| Est. Completion | 2027-03-27 |
| Phase | Phase 1 |
What the registry record for NCT06818812 still lists
NCT06818812 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Solid Tumors appearing as the primary indexed condition, and to 4 interventions - of which Cetuximab is the first listed.
NCT06818812 lists 9 locations in 9 states (California, Colorado, District of Columbia).
Frequently Asked Questions
What is clinical trial NCT06818812 about?
NCT06818812 is a clinical study titled "A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation". The purpose of this study is to evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation.
What is the current status of trial NCT06818812?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2025-03-27. Estimated completion is 2027-03-27.
What conditions does trial NCT06818812 study?
This clinical trial studies the following conditions: Solid Tumors.
What interventions are being tested in trial NCT06818812?
The interventions under investigation include: Cetuximab (DRUG), mFOLFIRINOX (DRUG), GEMNabP (DRUG), INCB186748 (DRUG).
Who is sponsoring clinical trial NCT06818812?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06818812 being conducted?
This trial has 9 study locations across California, Colorado, District of Columbia, Florida, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06818812's enrollment target sits among peer trials
30 108th of 125 higher than 18 of 125 other Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of INCB123667 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
RECRUITING · Phase 1
-
Study of AUBE00 in Patients With Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI